UCP2 and neoplasm: Based on the findings that exogenous expression of miR-133a in breast cancer cells attenuated its Doxorubicin resistance in vitro possibly by reducing the expression of UCP-2, we further explored the effect of overexpressing miR133a in tumor xenografts in vivo.